Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Fai...
Onconova Therapeutics, Inc. (ONTX)
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.onconova.com/investor-overview
Company Research
Source: GlobeNewswire
First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of the novel combination therapy in higher risk patients with Myelodysplastic Syndromes (MDS)Study demonstrates elimination of grade 3 or grade 4 urinary adverse events after implementation of mitigation strategies NEWTOWN, Pa., March 26, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, presented promising new clinical safety data from the expansion phase of a Phase 2 clinical trial at the Bone Marrow Failure Disease Scientific Symposium, held in Rockville, Maryland, on March 22-23, 2018. Oral rigosertib has been developed as a single agent and in combination with azacitidine. Previous studies have demonstrated that Low-Risk (LR) MDS patients with intermittent oral rigosertib treatment at a dose of 560 mg BID show a transfusion independence rate
Show less
Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONTX alerts
High impacting Onconova Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONTX
News
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024GlobeNewswire
ONTX
Earnings
- 11/14/23 - Beat
ONTX
Sec Filings
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- 3/14/24 - Form 144
- ONTX's page on the SEC website